Market Overview

UPDATE: Jefferies Lowers PT on Bristol-Myers Squibb Following Global Pharma Review

Share:
Related BMY
Pressure Biosciences CEO On Biological Samples: It's All About How You Break Open A Cell
Bristol-Myers Squibb, Cerner, General Motors, Monsanto: Fast Money Picks For November 25
TiGenix Seeks $53 Million IPO For Promising Stem Cell Treatments (Seeking Alpha)

In a report published Friday, Jefferies analyst Jeffrey Holford reiterated a Buy rating on Bristol-Myers Squibb Co. (NYSE: BMY), but lowered the price target from $53.50 to $53.00.

In the report, Jefferies noted, “We reiterate Novartis as our Top European and Global Pick with positive growth inflection potential in 2014 and significant restructuring optionality being key drivers. Abbott is our Top US Pick for similar reasons. We highlight Roche, Sanofi and AbbVie as potentially offering particularly attractive entry points following the recent sell-off. AstraZeneca is now our Least Preferred stock.”

Bristol-Myers Squibb Co. closed on Thursday at $46.17.

Latest Ratings for BMY

DateFirmActionFromTo
Oct 2016Hilliard LyonsUpgradesNeutralLong-Term Buy
Oct 2016Credit SuisseMaintainsNeutral
Sep 2016CitigroupMaintainsBuy

View More Analyst Ratings for BMY
View the Latest Analyst Ratings

Posted-In: Jefferies Jeffrey HolfordAnalyst Color Price Target Analyst Ratings

 

Related Articles (BMY)

View Comments and Join the Discussion!